insights_auto
Why is NVO up 2.22%?
Dive Deeperchevron_right
NVO:NYSE
Novo Nordisk A/S
$39.14
arrow_upward
+2.22%(+0.85) 1D
$39.73
arrow_upward
+1.51% (+0.59)todayPre-market
Closed: Oct 29, 4:00:08 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NVO...
Open
$38.67
High
$39.22
Low
$38.56
Mkt. cap
131.55B
Avg. vol.
13.30M
Volume
109.22K
Dividend
4.59%
Quarterly dividend
$0.45
Ex-dividend date
Aug 14, 2026
P/E ratio
10.02
52-wk high
$64.16
52-wk low
$35.12
EPS
$3.91
Beta
0.75
Shares outstanding
3.39B
No. of employees
67K
Open
$38.67
High
$39.22
Low
$38.56
Mkt. cap
131.55B
Avg. vol.
13.30M
Volume
109.22K
Dividend
4.59%
Quarterly dividend
$0.45
Ex-dividend date
Aug 14, 2026
P/E ratio
10.02
52-wk high
$64.16
52-wk low
$35.12
EPS
$3.91
Beta
0.75
Shares outstanding
3.39B
No. of employees
67K
News stories
From web sources and news partners
Traders Union
·
1 hour ago
NVO advances as buyers drive price higher ahead of earnings event
Yahoo! Finance Canada
·
11 hours ago
Novo Nordisk A/S (NVO) Seasonal Returns Chart - Yahoo Finance
Yahoo Finance
·
13 hours ago
Novo Has Big Plans for 2030. Should You Buy the Stock Now?
Profile
Novo Nordisk A/S, doing business as Novo, is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily obesity and diabetes medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Novo employs approximately 69,500 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark, and it became the highest valued company in Europe. Wikipedia
About Novo Nordisk A/S
CEOMike Doustdar
Employees66.7K
Founded1923
HeadquartersBagsværd, Capital Region of Denmark, Denmark
SectorPharmaceutical industry
Websitenovonordisk.com